Get the Stockscreener App
38.39
1.08%
-0.42
Royalty Pharma Plc stock is traded at $38.39, with a volume of 5.19M.
It is down -1.08% in the last 24 hours and down -3.03% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$38.81
Open:
$38.92
24h Volume:
5.19M
Relative Volume:
1.25
Market Cap:
$16.40B
Revenue:
$2.31B
Net Income/Loss:
$1.66B
P/E Ratio:
16.71
EPS:
2.297
Net Cash Flow:
$827.02M
1W Performance:
-3.37%
1M Performance:
-3.03%
6M Performance:
+8.85%
1Y Performance:
+52.28%
1-Day Range:
$37.98
$38.93
1-Week Range:
$37.88
$39.78
52-Week Range:
$24.05
$41.24
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
38.39 | 16.58B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Eventide Asset Management LLC Buys 41,830 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Main Street Financial Solutions LLC Buys 31,844 Shares of Royalty Pharma PLC $RPRX - MarketBeat
TD Cowen raises Royalty Pharma stock price target on growth outlook By Investing.com - Investing.com South Africa
Precision Trading with Royalty Pharma Plc (RPRX) Risk Zones - news.stocktradersdaily.com
TD Cowen Forecasts Strong Price Appreciation for Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
RPRX: TD Cowen Raises Price Target for Royalty Pharma | RPRX Sto - GuruFocus
TD Cowen raises Royalty Pharma stock price target on growth outlook - Investing.com Nigeria
Royalty Pharma (RPRX) PT Raised at TD Cowen; 'Best Ideas 2026: Unique Business' - StreetInsider
First Trust Advisors LP Has $39.78 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
California Public Employees Retirement System Sells 268,263 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Sells $913,526.10 in Stock - MarketBeat
Hsbc Holdings PLC Sells 77,498 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Holdings Raised by Amundi - MarketBeat
Denali enters into a $275M funding deal with Royalty Pharma - MSN
What Royalty Pharma (RPRX)'s Denali Rare-Disease Royalty Deal and Cash Surge Means For Shareholders - Sahm
Royalty Pharma (NASDAQ:RPRX) EVP Sells $4,374,700.00 in Stock - MarketBeat
11% Of This Royalty Pharma Insider's Holdings Were Sold - 富途牛牛
Royalty Pharma Insider Sold Shares Worth $4,375,008, According to a Recent SEC Filing - marketscreener.com
What's Going On With Denali Therapeutics Stock Friday?Denali Therapeutics (NASDAQ:DNLI) - Benzinga
Royalty Pharma (RPRX): Assessing Valuation After a Strong Multi‑Month Share Price Rally - Sahm
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Prime Publishers, Inc.
Is It Too Late to Reassess Royalty Pharma After Its 52% Surge in 2025? - Yahoo Finance
Royalty Pharma PLC $RPRX Shares Acquired by Schroder Investment Management Group - MarketBeat
Denali makes $275m funding agreement with Royalty Pharma - Yahoo Finance
Will Royalty Pharma plc (RPD) stock maintain strong growth2025 Valuation Update & Reliable Volume Spike Trade Alerts - Newser
Royalty Pharma (NASDAQ:RPRX) CFO Sells $2,774,234.34 in Stock - MarketBeat
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $931,686.69 in Stock - MarketBeat
Is Royalty Pharma plc stock a good choice for value investors2025 Market Sentiment & Verified Technical Trade Signals - Newser
Denali Therapeutics stock rises on $275 million royalty deal with Royalty Pharma - Investing.com Australia
Denali, Royalty Pharma Ink $275Mln Royalty Financing Agreement - Nasdaq
Denali Therapeutics and Royalty Pharma ink $275 million funding deal By Investing.com - Investing.com Nigeria
Royalty Pharma, Denali Sign $275 Million Hunter Syndrome Treatment Royalty Deal - marketscreener.com
Denali Therapeutics and Royalty Pharma ink $275 million funding deal - Investing.com
Denali Therapeutics enters $275 million royalty funding agreement with Royalty Pharma - Investing.com
How Royalty Pharma plc (RPD) stock correlates with oil marketsMarket Activity Summary & Capital Efficiency Focused Strategies - Newser
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Agreement for Tividenofusp Alfa Development - Quiver Quantitative
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement - The Manila Times
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement - The Manila Times
Denali Therapeutics (Nasdaq: DNLI) lands $275M, 9.25% tividenofusp alfa royalty deal - Stock Titan
OMERS ADMINISTRATION Corp Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc (RPD) stock attractive post correction2025 Trading Volume Trends & Real-Time Market Sentiment Alerts - Newser
How Royalty Pharma plc (RPD) stock trades pre earningsQuarterly Profit Summary & Weekly High Return Forecasts - Newser
How Royalty Pharma plc (RPD) stock performs in easing cyclesJuly 2025 Action & Community Consensus Stock Picks - Newser
Arrowstreet Capital Limited Partnership Purchases 1,615,706 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma EVP Coyne sells shares worth $2.77 million By Investing.com - Investing.com Nigeria
Urist Marshall sells Royalty Pharma (RPRX) shares worth $1.66 million By Investing.com - Investing.com Nigeria
Royalty Pharma EVP Coyne sells shares worth $2.77 million - Investing.com
Transcript : Royalty Pharma plc Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 03 - marketscreener.com
Urist Marshall sells Royalty Pharma (RPRX) shares worth $1.66 million - Investing.com
100,000 Shares in Royalty Pharma PLC $RPRX Acquired by Watchtower Advisors LP - MarketBeat
Norges Bank Invests $181.39 Million in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Royalty Pharma Plc Stock (RPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Urist Marshall | EVP, Research & Investments |
Dec 05 '25 |
Sale |
39.15 |
18,242 |
714,224 |
7,398 |
| Lloyd George W. | EVP, Investments & CLO |
Dec 03 '25 |
Sale |
39.77 |
110,000 |
4,375,008 |
110,000 |
| Coyne Terrance P. | EVP & CFO |
Dec 01 '25 |
Sale |
39.87 |
69,582 |
2,773,956 |
47,260 |
| Urist Marshall | EVP, Research & Investments |
Dec 01 '25 |
Sale |
39.93 |
23,333 |
931,633 |
183,334 |
| Urist Marshall | EVP, Research & Investments |
Dec 01 '25 |
Sale |
39.90 |
18,242 |
727,856 |
25,640 |
0.72%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):